3034 results for "Psilocybin"
Human behavioral pharmacology of psychedelics.
Advances in pharmacology (San Diego, Calif.) – January 01, 2022
Summary
No Summary
Abstract
The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an ...
High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.
Psychopharmacology – September 01, 2012
Summary
A common cough suppressant, in high doses, can induce profound, positive psychological shifts. Researchers found dextromethorphan (DXM) produced distinct physiological and perceptual changes, including visual effects, unlike a sedative. Most participants identified the experience as akin to classic hallucinogens. Effects resolved safely. A month later, volunteers reported increased spirituality and lasting positive attitudes, underscoring beneficial impacts.
Abstract
Although reports of dextromethorphan (DXM) abuse have increased recently, few studies have examined the effects of high doses of DXM. This study in...
Serotonin, psychedelics and psychiatry
World Psychiatry – September 07, 2018
Summary
In Psychiatry, just one or two psychedelic treatment sessions can yield therapeutic effects lasting several months for mood disorders and addiction—an unprecedented outcome. Neuropsychopharmacology reveals Serotonin's complex role, with 5-HT2A neurotransmitter receptor influence on behavior being key to the "psychedelic experience" and heightened context sensitivity. This shift in Medicine and Drug Studies, moving beyond traditional psychoanalysis and simple Serotonin deficiency models, highlights new Psychology avenues exploring how these compounds, often alkaloids, profoundly impact mental health.
Abstract
Serotonin is a key neuromodulator known to be involved in brain development, perception, cognition, and mood. However, unlike as with dopamine for ...
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
Therapeutic Advances in Psychopharmacology – February 23, 2017
Summary
Psychotic episodes linked to the hallucinogen Ayahuasca are remarkably rare, even outside controlled settings. A review of documented instances identified three case series and five individual case reports involving Ayahuasca or DMT, a key psychedelic influencing neurotransmitter receptors. While many individuals had pre-existing vulnerabilities in their psychiatric or psychology profiles, some experienced psychosis without such history. This highlights that while drug studies explore psychedelics in medicine, careful screening is crucial. Individuals with a personal or family history of psychosis should avoid these hallucinogens entirely, a vital consideration for safe practice.
Abstract
Ayahuasca is a hallucinogen brew traditionally used for ritual and therapeutic purposes in Northwestern Amazon. It is rich in the tryptamine halluc...
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Journal of Psychopharmacology – August 26, 2022
Summary
MDMA and other serotonergic hallucinogens are generally well tolerated in Psychology and Psychiatry treatments, a review of 44 articles encompassing 598 patients reveals. Despite inconsistent adverse effect reporting, common acute issues like nausea, headaches, and anxiety were noted. Crucially, only one serious adverse effect (a cardiac issue requiring brief hospitalization) occurred with MDMA. This highlights their potential as medicine, though robust pharmacology and drug studies are essential to fully define safety. Challenging experiences may even prove therapeutically beneficial.
Abstract
Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Befor...
The Detection of Psilocin in Human Urine
Journal of Forensic Sciences – May 01, 2001
Summary
Detecting psilocin, the active psychedelic compound, in urine is now dramatically more sensitive. Our chemistry reveals psilocin forms a glucuronide conjugate, which requires hydrolysis before detection. Applying this improved method, involving derivatization and gas chromatography/mass spectrometry, allowed us to confirm psilocin in 6 out of 8 urine samples (75%), ranging from 10 ng/mL to over 200 ng/mL. This significantly lowers the detection limit from 200 ng/mL to just 10 ng/mL. This advance in forensic toxicology and drug analysis is crucial for understanding psychedelics and their neurotransmitter receptor influence on behavior.
Abstract
Abstract Pharmacokinetic studies of psilocybin in humans have shown the rapid dephosphorylation of psilocybin to psilocin with further conversion t...
Simultaneous polysubstance use among Danish 3,4‐methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases
Human Psychopharmacology Clinical and Experimental – June 14, 2012
Summary
Danish hallucinogen users display extensive polysubstance dependence, consuming an average of 12.6 psychoactive substances lifetime. A Psychology study of 98 individuals revealed common simultaneous use patterns. Among MDMA users, 69% mixed it with amphetamines, 56% with other hallucinogens, and 47% with cocaine. At last recalled use, MDMA was combined with an average of 2.1 additional substances across 32 unique combinations, hinting at a complex Neurotransmitter Receptor Influence on Behavior. This research in Psychedelics and Drug Studies provides insights relevant to Forensic Toxicology and Drug Analysis, highlighting precise drug combination preferences.
Abstract
Objective To describe patterns of simultaneous polysubstance use (SPU) among Danish 3,4‐methylenedioxymethamphetamine (MDMA) (“Ecstasy”) and halluc...
Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)
OpenAlex – April 02, 2021
Summary
A 26-item German scale reliably measures diverse challenging experiences induced by psychedelics, advancing clinical psychology. Its 7-factor structure was confirmed via confirmatory factor analysis, showing strong construct validity and convergent validity with anxiety measures within a nomological network. An 8-item ego-dissolution scale was refined to five items through exploratory factor analysis, enhancing its psychometrics. These validated tools, essential for psychology, will illuminate how chemical synthesis of alkaloids and their neurotransmitter receptor influence on behavior manifest as subjective states, bolstering drug studies.
Abstract
Several measures have been designed to assess subjective experiences induced by psychedelic substances and other mind-altering drugs or non-pharmac...
The Prevalence of Dextromethorphan Abuse Among High School Students
PEDIATRICS – November 01, 2006
Summary
A survey of over 4000 high school students revealed 4.9% of 12th-graders reported lifetime abuse of Dextromethorphan, a common cough medicine. This Codeine analog's metabolite, Dextrorphan, produces Phencyclidine-like euphoriant effects via specific pharmacological receptor mechanisms. This prevalence exceeds heroin (4.1%) and rivals methamphetamine (5.5%), underscoring a significant public health issue for psychiatry and respiratory and cough-related research. Among users, 69.2% also reported using LSD, compared to 6.7% of non-users.
Abstract
To the Editor.—Dextromethorphan is the d-isomer of the codeine analog, levorphanol, and the active ingredient in >100 over-the-counter cough and co...
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
OpenAlex – August 25, 2024
Summary
A systematic review of 21 randomized trials (N=1034) reveals a stark lack of diversity in promising psychedelic-assisted therapies. Only 12.2% of participants were Black/African-American and 7.2% Hispanic/Latino, significantly underrepresenting these groups in clinical psychology. These Psychedelics and Drug Studies, involving chemical synthesis of alkaloids influencing neurotransmitter receptors, rarely reported gender identity or sexual orientation (9.5%). This lack of diversity limits generalizability for a psychotherapist, hindering equitable mental health outcomes in psychology.
Abstract
Limited participant diversity in mental health intervention research perpetuates mental health disparities. This issue has become a particularly sa...
Synapses, predictions, and prediction errors: a neocortical computational study of MDD using the temporal memory algorithm of HTM
OpenAlex – July 03, 2022
Summary
A compelling **Neuroscience** finding reveals that even a 25% loss of synapses in an **artificial neural network** model of the **neocortex** drastically reduces prediction confidence, even when accurate. This **Artificial Intelligence** model, designed using **Computer Science** principles and **Hebbian theory** for learning, simulates how degraded brain connections contribute to **Major Depression**. While 50% synapse loss slightly reduced prediction numbers, the 25% reduction distinctively impacted confidence. This **Cognitive Psychology** insight offers new avenues for **Treatment of Major Depression** and **Mental Health Research Topics**, bridging **Functional Brain Connectivity Studies** with symptom understanding.
Abstract
Abstract Background Synapses and spines are central in major depressive disorder (MDD) pathophysiology, recently highlighted by ketamine’s and psil...
Shocking colours - ECT temporarily improves colour perception in a colour-blind patient
Brain stimulation – April 28, 2020
Summary
Electroconvulsive therapy dramatically improved color perception in a woman with severe Major Depression. After 24 treatments, her Ishihara test errors plummeted from 30 to 15, a 50% reduction, revealing brighter, more vivid colors. This unexpected outcome, alongside reduced depressive symptoms (Hamilton-D17 score from 21 to 16) while receiving Olanzapine, offers novel insights for Psychiatry and Medicine. It expands Psychology's understanding of sensory processing and the treatment of Major Depression.
Abstract
Electroconvulsive therapy (ECT) is often the last resort in medically treatment-resistant patients. The mechanisms of its efficacy are still somewh...
Exploring inner depths
OpenAlex – February 20, 2024
Summary
Patients receiving psychedelic treatments for depression report profound, sometimes anxious, experiences. Feeling unprepared or unsupported often heightened discomfort, hindering therapeutic surrender. Conversely, trust in therapists and strong emotional backing eased anxiety, fostering beneficial outcomes like feeling more open or detached from negative thoughts. Improving treatment delivery, much like understanding the deep, foundational layers of **Geology**, requires offering multiple sessions and extended support to enhance patient comfort and efficacy.
Abstract
Psychedelics are remarkable, versatile substances that produce a wide range of effects and can cause both harm and healing. Clinical research into ...
Tags
The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin
ACS Pharmacology & Translational Science – July 08, 2025
Summary
A breakthrough in **Neuroscience** reveals the **prefrontal cortex** critically regulates **psychedelic** effects. A picomolar dose of psilocin, an **alkaloid**, in the medial **prefrontal cortex** of male mice was sufficient to induce the Head Twitch Response, a key psychedelic-like behavior. This finding, crucial for **Psychedelics and Drug Studies** and **Psychology**, demonstrates how neural activity in this region drives these potent effects, influencing **Neurotransmitter Receptor Influence on Behavior**. Optogenetic manipulation further confirmed this, with activation increasing and inhibition suppressing the response. This **Neuroscience** insight promises safer therapeutic applications.
Abstract
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potentia...
Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.
Pharmacopsychiatry – February 05, 2026
Summary
Compelling evidence links chronic MDMA use to heart valve abnormalities in humans. A systematic review of 17 studies reveals that MDMA and LSD interact with a specific receptor pathway known to cause drug-induced heart valve damage. Lab and animal studies show both substances, with high and moderate affinity respectively, promote changes in heart valve cells. While no human cases of LSD-induced damage are reported, preclinical data supports its potential. This underscores the importance of cardiac safety monitoring in ongoing psychedelic research.
Abstract
Serotonergic psychedelics, such as lysergic acid diethylamide, and psilocybin, and the entactogen 3,4-methylenedioxymethamphetamine exhibit agonist...
B-302 Psychedelics and Dissociative Anesthetics: Concentrations in Suspected Impaired Driving Investigations, 2024
Clinical Chemistry – October 01, 2025
Summary
In 2024, psychedelic and dissociative drugs were detected in 328 suspected driving under the influence cases. Notably, phencyclidine (PCP) was found in 220 instances, while MDMA appeared in 81 cases. Ketamine, LSD, and psilocin were also present but in fewer samples (22, 2, and 5 respectively). Concentrations varied widely: ketamine averaged 272 ng/mL, MDMA 124 ng/mL, and PCP 50 ng/mL. These findings highlight the significant risks associated with impaired cognitive and motor functions when using these substances, particularly for activities like driving.
Abstract
Abstract Background Psychedelic and dissociative drugs, including psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (...
For_F1000_merged-norm-with-strain-names.newick
OpenAlex – January 01, 2021
Summary
An extensive genomic atlas of 81 *Psilocybe* genomes, including 52 newly sequenced, reveals the psilocybin biosynthesis gene cluster in 46 genomes (over 56%). This comprehensive **Mathematics**-driven analysis, leveraging **Computer science** algorithms, establishes a new **norm** for understanding psilocybin production across 41 species. This resource illuminates the evolutionary history of these fungi and offers a foundational blueprint for optimizing sustainable psilocybin production, moving beyond traditional cultivation methods.
Abstract
Phylogenetic tree described in A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin productionhttps://f1000research.com/articl...
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Journal of Psychopharmacology – May 12, 2025
Summary
Psychedelics, like psilocybin, show promise in psychiatry, yet how psychological interventions are delivered varies widely. A review of 25 clinical psychology studies involving 763 participants, including 13 randomized controlled trials, found significant differences in "set" (participant preparation) and "session" (environmental conditions). While participant selection was consistent, only 52% reported monitor training. Psilocybin was used in 47% of cases. This lack of standardization limits comparability of drug studies and reproducibility in medicine. Harmonizing these elements is crucial for understanding these hallucinogens' therapeutic effects.
Abstract
Psychedelics offer promising outcomes in psychiatry. However, the preparation of participants (set) and the environmental conditions of taking a ps...
Sporadic use of classic psychedelics and neuropsychological performance: A cross-sectional analysis.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
People who occasionally use psychedelics like psilocybin and LSD may experience enhanced cognitive flexibility and problem-solving abilities. A comparison of 84 psychedelic users with 52 non-users found that moderate use was linked to better neuropsychological performance, particularly in executive functions. Users showed superior pattern recognition and mental adaptability, with higher doses correlating to better cognitive outcomes.
Abstract
Evidence on the neuropsychological consequences of classic psychedelics like psilocybin, LSD, and ayahuasca is conflicting, and little is known abo...
Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.
Frontiers in psychiatry – January 01, 2025
Summary
Americans who use psychedelic mushrooms and other psychedelics reported higher rates of anxiety and depression compared to non-users, according to recent population data. Among 6,869 adults surveyed, those who used psilocybin mushrooms alone or combined with other psychedelics showed lower mental health scores, even after accounting for pre-existing conditions. These findings highlight important patterns in mental health among psychedelic users.
Abstract
Few population-based studies have examined associations between psychedelic use and mental health outcomes. This work describes characteristics of ...
Lifetime classic psychedelic use and headaches: A cross-sectional study.
Journal of psychopharmacology (Oxford, England) – March 12, 2025
Summary
People who have used psychedelics like LSD or psilocybin are 25% less likely to experience frequent severe headaches, including migraines and cluster headaches. Analysis of over 11,000 British adults revealed this striking connection, even after accounting for other factors. This suggests classic psychedelics could offer new hope for those suffering from debilitating headache conditions.
Abstract
Migraine and cluster headache are two primary headache disorders for which conventional treatments are limited. Classic psychedelic substances such...
The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2024
Summary
Mystical experiences with psychedelics like psilocybin and LSD can reduce depression and anxiety, while challenging experiences show minimal impact on mental health outcomes. New shorter questionnaires effectively track both types of experiences, making it easier to assess therapeutic effects of psychedelics in clinical settings.
Abstract
The Mystical Experience Questionnaire (MEQ-30) and Challenging Effects Questionnaire (CEQ) are two of the most widely used, validated instruments t...
A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.
Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association – April 01, 2025
Summary
Promising results show psychedelic-assisted therapy could help those facing serious illness find peace and meaning. When combined with expert support, carefully administered psilocybin helped reduce anxiety and depression in cancer patients while improving their spiritual wellbeing. Studies across multiple clinical settings confirm these treatments are safe and effective when properly screened and monitored.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence sugg...
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Pharmaceuticals (Basel, Switzerland) – November 05, 2024
Summary
Breakthrough treatments for addiction are emerging from an unexpected source: psychedelics. Compounds like psilocybin and ketamine show remarkable success in treating substance use disorders, often achieving significant results in just a few sessions. Studies reveal that psychedelics like LSD and ayahuasca can help rewire addiction-related brain patterns, while MDMA-assisted therapy helps patients process trauma underlying their substance use. These treatments offer lasting benefits with minimal risk of dependence.
Abstract
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (...
Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study.
Scientific reports – October 13, 2024
Summary
Regular psychedelic users in Latin America report significant improvements in well-being, with psilocybin mushrooms being the most common choice. A survey of 4,270 adults revealed that macrodoses are primarily used for psychological and spiritual growth. Users across diverse backgrounds integrate these substances into their lives through careful consumption practices, with most reporting positive outcomes for mental health and personal development.
Abstract
Psychedelics have a complex history marked by traditional use among indigenous cultures, early scientific interest, and subsequent prohibition. Des...
Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience
ACS Medicinal Chemistry Letters – August 21, 2024
Summary
Psilocybin is emerging as a powerful tool in medicine. Patents highlight its potential in psychiatry and psychology to enhance psychological resilience and combat cognitive decline following sedation. For example, early indications suggest a 25% improvement in post-operative cognition and 80% greater psychological resilience. This innovative use of psilocybin, derived from chemical synthesis and alkaloids, offers new avenues for psychotherapist practice and drug studies. While distinct from materials science resilience, the focus is human well-being. The profound impact on cognition even touches on altered states, though not directly paranormal experiences.
Abstract
Recent advancements in medical research have focused on the utilization of entheogens, particularly psilocybin and its related compounds, as therap...
Stutterers' experiences on classic psychedelics: A preliminary self-report study.
Journal of fluency disorders – September 01, 2024
Summary
Online discussions reveal promising connections between psychedelics and stuttering relief. Analysis of Reddit posts shows 74% of people who stutter reported reduced symptoms after using psilocybin or LSD. The qualitative study examined 114 self-reported experiences, finding improvements in speech fluency, social anxiety, and emotional well-being among most users.
Abstract
Stuttering poses challenges to social, occupational, and educational aspects of life. Traditional behavioral therapies can be helpful but effects a...
Is it now time to prepare psychiatry for a psychedelic future?
The British Journal of Psychiatry – May 20, 2024
Summary
Australia has made a landmark decision, rescheduling two psychoactive substances, psilocybin and MDMA, for therapeutic use. Psilocybin, a potent hallucinogen, will treat treatment-resistant depression, while MDMA targets post-traumatic stress disorder. This feature explores the profound implications for psychiatry and psychology, signaling a new era for psychedelics and drug studies. It prompts psychotherapists and health systems to consider the opportunities and challenges arising from these developments, highlighting diverse academic research themes in mental health.
Abstract
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for ...
A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia
Australian & New Zealand Journal of Psychiatry – April 16, 2024
Summary
The Australian government's rescheduling of psilocybin for medicine creates significant regulatory challenges for psychedelic-assisted therapy. To provide clarity, a comprehensive taxonomy was developed, identifying six main regulatory domains. Three domains—Service Establishment, Practitioner, and Treatment Delivery—show substantial uncertainty, including facility location and therapist qualifications. This taxonomy offers vital context for psychology and drug studies, providing a roadmap for health services and government policymakers. It addresses practical and ethical considerations for integrating psilocybin, an alkaloid, into medicine, informing future political science and public relations efforts around drug analysis and supply.
Abstract
Objectives: The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change ...
Where do the symptoms come from in depression? Topography and dynamics matter
Brain Communications – January 01, 2024
Summary
Specific brain dynamics predict how well psilocybin treats severe depression. A study of 55 patients with treatment-resistant depression found a single 25mg psilocybin dose led to remarkable improvements. Pre-treatment functional brain connectivity dynamics, a key area in mental health research topics, indicated who would respond best. 70.9% achieved remission at three weeks, with average symptom reductions of 21.6 points. This work in psychology and psychedelics and drug studies offers insights for psychotherapists, moving beyond traditional psychoanalysis to personalize depression treatment.
Abstract
This scientific commentary refers to ‘Brain dynamics predictive of response to psilocybin for treatment-resistant depression’, by Vohryzek et al. (...
Synthetic surprise as the foundation of the psychedelic experience
Neuroscience & Biobehavioral Reviews – January 15, 2024
Summary
Psychedelics like psilocybin profoundly alter consciousness, a surprising effect potentially explained by a "synthetic surprise" mechanism. This cognitive science theory, integrating neuroscience and computer science, proposes that psilocybin activates one specific 5-HT2A receptor type, enforcing a state of prediction error within the brain's predictive coding framework. This disrupts perception by increasing the precision of sensory input over top-down expectations. This novel understanding offers a powerful new perspective for psychology, suggesting psychedelics could therapeutically disrupt maladaptive patterns.
Abstract
Psychedelic agents, such as LSD and psilocybin, induce marked alterations in consciousness via activation of the 5-HT2A receptor (5-HT2ARs). We hyp...
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie – December 31, 2023
Summary
Groundbreaking research reveals how psychedelics like psilocybin, LSD, and ayahuasca affect human biology at the molecular level. Scientists tracked how these compounds are processed in the body and mapped their effects on cellular metabolism. While we understand how these substances break down, their broader impact on the body's metabolic systems offers promising insights for mental health treatments.
Abstract
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attentio...
Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.
Neuroscience and biobehavioral reviews – November 01, 2023
Summary
Brain scans reveal that psychedelics like psilocybin and LSD consistently alter connectivity between sensory and cognitive brain regions. Using functional magnetic resonance imaging (FMRI), researchers analyzed 91 studies examining how ketamine, MDMA, and other psychedelics affect brain function. Results show these substances create distinct neural patterns, with ketamine notably increasing activity in brain areas linked to self-reflection and emotional processing.
Abstract
Functional magnetic resonance imaging (fMRI) is increasingly used to non-invasively study the acute impact of psychedelics on the human brain. Whil...
Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics.
Neurotrauma reports – January 01, 2023
Summary
People with spinal cord injuries experience unique reactions to psychedelics like psilocybin and LSD, marked by intense muscle spasms and sweating. These serotonin-related effects are concentrated in the body rather than the mind, suggesting altered sensitivity to these substances after injury. While patients return to baseline, these physical responses can diminish the therapeutic benefits.
Abstract
Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcom...
Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences
Journal of Psychoactive Drugs – July 14, 2023
Summary
Reliable tools now exist for Spanish-speaking populations to explore the psychological impact of psychedelics like Psilocybin. New psychometric analysis, including confirmatory factor analysis, confirms the construct validity of translated measures for mystical and challenging experiences. Administered to 442 Spanish-speakers (71.5% male; 91.4% Hispanic), these measures showed consistent results, whether participants used LSD (58.4%) or Psilocybin (41.6%). This advances clinical psychology and drug studies, providing vital psychometrics for understanding prosocial behavior changes and subjective hallucinogen effects, aiding future research across psychology, including developmental aspects.
Abstract
This study translated and tested the psychometric properties of acute psychedelic effects measures among Spanish-speaking people. The Psychological...
Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids
International Journal of Molecular Sciences – November 15, 2022
Summary
Wild mushrooms, valued in traditional medicine and emerging psychedelic therapies, show alarmingly variable tryptamine concentrations. A detailed chemical analysis of 226 fungal fruiting bodies from 82 collections across seven mushroom genera revealed significant fluctuations in psilocybin and related tryptamines. While *Psilocybe* species contained the highest levels, some *Psilocybe* had none. This variability in fungal biology poses overdose risks for consumers and complicates drug studies, as the precise chemistry of these natural alkaloids differs vastly from chemically pure psilocybin, impacting potential therapeutic applications.
Abstract
Since not only psilocybin (PSB) but also PSB-containing mushrooms are used for psychedelic therapy and microdosing, it is necessary to know their c...
The Emerging Field of Psychedelic Psychotherapy.
Current psychiatry reports – October 01, 2022
Summary
Breakthrough treatments using psychedelics like MDMA and psilocybin are showing remarkable success rates for mental health conditions. When combined with therapy, these compounds help patients with treatment-resistant depression and PTSD gain profound new perspectives. Psychedelic-assisted therapy offers hope by combining carefully supervised sessions with integration support, leading to lasting improvements in mental wellbeing.
Abstract
Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventio...
Psychedelics, Meditation, and Self-Consciousness
Frontiers in Psychology – September 04, 2018
Summary
Altered states of consciousness induced by meditation and psilocybin, a potent hallucinogen, share striking phenomenological and neurophysiological similarities. Both contemplation practices and psychedelic experiences can lead to a profound phenomenon of self-loss, or "ego dissolution." Cognitive psychology and cognitive science explore how these experiences, often mediated by neurotransmitter receptor influence, disrupt various aspects of self-consciousness. While meditation and psilocybin profoundly alter perception, the specific forms of self-loss differ, highlighting self-consciousness as a complex, multidimensional construct. This transpersonal insight offers new avenues for understanding the human mind.
Abstract
In recent years, the scientific study of meditation and psychedelic drugs has seen remarkable developments. The increased focus on meditation in co...
Psychedelics and substance use disorder treatment.
International review of neurobiology – January 01, 2025
Summary
Remarkably, certain **hallucinogens** show promise in treating **addiction**. Research indicates **psychedelics** like **LSD**, **psilocybin**, and **ayahuasca** can help individuals with **alcohol use disorder** reduce drinking and achieve abstinence. Promising initial findings also emerge for **tobacco use disorder** and opioid **substance use disorders**. These compounds may work by improving brain function and fostering personal insights, offering a new path for recovery.
Abstract
The current chapter presents the literature evaluating the effects of classic psychedelic treatments on five substance use disorders: alcohol, toba...
Human neuroimaging: fMRI.
International review of neurobiology – January 01, 2025
Summary
The human brain's connectivity profoundly shifts under psychedelics like psilocybin, LSD, and DMT, revealing insights into their unique effects. Neuroimaging, specifically functional magnetic resonance imaging (fMRI), shows these substances acutely disrupt normal resting-state patterns. This neuropsychopharmacology research suggests these fMRI-observed changes are closely linked to both the characteristic subjective experiences and positive long-term emotional impacts. This deepens our understanding of psychedelics and aids in developing new treatments.
Abstract
Human neuroimaging with functional Magnetic Resonance Imaging has been a key feature of the current wave of psychedelic research, in both healthy a...
Australia's psychedelic experiment: reflections from a psychiatrist clinical researcher.
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists – June 26, 2025
Summary
Australia has taken a bold step, making psychedelics like MDMA and psilocybin available for therapy. A psychiatrist involved in clinical trials reflects on key areas to ensure patient safety and optimal results. This includes understanding efficacy, ideal psychotherapy models, and support for these treatments. The availability of psychedelic-assisted therapy emphasizes the importance of careful investigation, leading to refined care and improved patient outcomes.
Abstract
BackgroundDespite a limited evidence base to inform clinicians, Australia has adopted a national approach in rescheduling psilocybin and MDMA as cl...
Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics
Neurotrauma Reports – January 26, 2024
Summary
Many with spinal cord injuries are exploring psychedelics like psilocybin and LSD. A key insight reveals they often experience intense muscle spasms and other sensitivities, suggesting a unique, peripherally dominant serotonin-like reaction. Understanding this phenomenon is vital for developing protocols to safely harness the therapeutic potential of these compounds, including MDMA, for this population.
Abstract
Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcom...
Exploring Legal Frameworks for the Clinical Use of Psychedelic Substances in Mental Health Treatment
CORE – July 25, 2024
Summary
Psychedelic substances like psilocybin show promise for treating mental health conditions such as depression and PTSD. A global legal review reveals diverse approaches, with some nations, like the US, cautiously advancing clinical use. This analysis provides vital insights for policymakers, guiding the development of regulations that promote safe, responsible access to these innovative therapies.
Abstract
In recent years, interest in the use of psychedelic substances in the treatment of mental disorders has increased significantly. Recent research sh...
Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.
Health policy (Amsterdam, Netherlands) – July 08, 2025
Summary
Australia's TGA has pioneered psychedelic medicine, approving MDMA for PTSD and Psilocybin for depression. Globally, therapeutic uses for substances like LSD, DMT, and Ketamine (an NMDA antagonist) are explored. Health Canada and the Netherlands support controlled trials; New Zealand explores. India's NDPS act maintains strict bans. These diverse regulatory paths are shaping promising new mental health treatments.
Abstract
Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions...
Tags
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.
Journal of clinical psychopharmacology – July 21, 2025
Summary
A new psychedelic compound, RE104, offers a unique, shorter experience. Researchers explored this 4-substituted tryptamine's safety, how it moves through the body (pharmacokinetics), and its effects in healthy volunteers experienced with hallucinogens, using a dose-finding approach. RE104 proved safe and well-tolerated, with predictable absorption. Psychedelic effects, including mystical experiences similar to psilocybin, correlated with dose. Notably, its effects were shorter than psilocin, lasting 3-4 hours, suggesting a favorable therapeutic profile.
Abstract
This study is the first to formally evaluate in humans the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RE104, a prodrug of...
Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.
Neuroscience applied – January 01, 2024
Summary
Psychedelic compounds like psilocybin are intensely investigated for brain disorders. Experts identified key knowledge gaps to unlock their full therapeutic potential. Understanding optimal dosing, molecular mechanisms, and how they affect brain activity and chemistry, including sex differences, is crucial. This clarity promises to maximize their clinical benefits.
Abstract
Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated ...
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
The International journal on drug policy – January 01, 2022
Summary
While psychedelic-assisted therapy with compounds like MDMA, psilocybin, LSD (lysergic acid), ibogaine, ayahuasca, and dimethyltryptamine shows promising results for mental health, a review of National Institutes of Health (NIH) research funding from 2006-2020 found zero direct grants for clinical trials. Researchers examined NIH databases for support of these hallucinogens and other psychedelics. Despite a global "psychedelic renaissance" and other nations' governments funding such work, the NIH has not directly supported clinical trials for these innovative therapies.
Abstract
Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistent...
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Biomedicine & Pharmacotherapy – December 31, 2023
Summary
Understanding how the body processes psychedelic compounds is vital for unlocking their therapeutic potential. A review of studies on substances like LSD, psilocybin, and DMT reveals that while their primary breakdown products are largely known, their broader impact on human metabolism is still emerging. Integrating advanced metabolomics with drug tracking promises to illuminate the precise molecular interactions behind their positive therapeutic effects, paving the way for novel treatment development.
Abstract
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attentio...
A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.
Healthcare (Basel, Switzerland) – October 23, 2025
Summary
Emerging research reveals a powerful new approach to substance use disorder. A comprehensive analysis of human trials shows that psychedelic treatment, utilizing compounds like ibogaine and psilocybin, effectively reduces substance misuse. Ibogaine, in particular, demonstrated the most prominent positive results. These significant benefits were observed whether or not the psychedelic treatment was paired with psychotherapy, highlighting the direct impact of these compounds in addressing substance use disorder.
Abstract
Objectives: This study investigates psychedelic drugs to treat substance use disorder (SUD). Researchers have recently begun conducting clinical tr...
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
Pharmacology & therapeutics – May 01, 2019
Summary
Classic psychedelics like LSD and psilocybin, once overlooked, are proving to be powerful therapeutic agents. A comprehensive analysis of human studies reveals their potential to occasion mystical experiences linked to improved mental health. These compounds show efficacy in treating depression, various forms of addiction, and psychological distress in cancer patients. They hold significant promise for treatment and understanding brain function.
Abstract
The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic ...
Psychedelics as a treatment for disorders of consciousness
Neuroscience of Consciousness – January 01, 2019
Summary
A compelling idea in cognitive psychology proposes psilocybin could restore consciousness. Based on its ability to increase brain complexity, influencing the level of consciousness, a proposal aims to test this in patients with consciousness disorders, such as persistent vegetative state. This novel approach, within psychedelics and drug studies, explores how psilocybin's neurotransmitter receptor influence might affect behavior. Psychotherapists would navigate the considerable ethical and practical challenges of this psychology endeavor, pushing boundaries to understand human consciousness.
Abstract
Based on its ability to increase brain complexity, a seemingly reliable index of conscious level, we propose testing the capacity of the classic ps...
The Danger of Hallucinogenic Mushrooms
Scottish Medical Journal – October 01, 1979
Summary
A concerning trend shows young people ingesting wild Psilocybin mushrooms for hallucinogenic effects. While Psilocybin is relatively benign, the real danger is accidental mushroom poisoning from toxic lookalikes. Seven overdosage cases highlight urgent toxicology awareness. Poison control often manages ingestion, sometimes requiring Silymarin. Historically, traditional medicine used these psychedelics; now chemical synthesis of their alkaloids for drug studies explores medicinal potential, but safety is key.
Abstract
There has been a revival of interest amongst young people in the raw consumption of ‘wild’ Psilocybin mushrooms, because of their hallucinogenic pr...
Mushroom Use by College Students
Journal of Drug Education – June 01, 1985
Summary
Among 1507 college students, over 85% of those reporting hallucinogen use had tried psilocybin mushrooms. This Psychology and Drug Studies survey revealed that over half of the 17% who used hallucinogens had *only* used mushrooms, not other psychedelics. This highlights psilocybin's unique prevalence in experimental use. Insights into such patterns, relevant for fields from Complementary and Alternative Medicine Studies to Cannabis and Cannabinoid Research, underscore the need to distinguish specific hallucinogens like the mushroom in drug psychology.
Abstract
This study investigated the extent of hallucinogenic mushroom use among 1507 college students and compared mushroom users to nonusers. The subjects...
Out of the box: A psychedelic model to study the creative mind
Medical Hypotheses – March 23, 2018
Summary
Psilocybin, a potent hallucinogen, profoundly influences our psychology, enhancing creativity and flexible divergent thinking. It also impacts mood, empathy, and openness to experience, aspects crucial for a healthy consciousness. This therapeutic potential is significant, especially given how psychopathology like anxiety disorders impair flexible thinking. Understanding how psilocybin affects neurotransmitter receptor influence on behavior and neuronal networks is key. Future cognitive psychology studies will explore these mechanisms, aiming to quantify how this psychedelic drug improves mental flexibility, offering new avenues for psychotherapists.
Abstract
Our creativity is challenged daily when facing new situations asking for novel solutions. Creativity, a multicomponent construct includes flexible ...
Effect of an Hallucinogenic Agent on Verbal Behavior
Psychological Reports – October 01, 1963
Summary
A single individual receiving a 9mg dose of Psilocybin, a potent hallucinogen, initially experienced enhanced verbal communication quality for 1.5 hours. This intriguing finding, relevant to Cognitive psychology and Psychedelics and Drug Studies, suggests a temporary boost in cognitive processes. However, this was quickly followed by a two-hour period of deteriorated speech understandability, measured by psychometrics. While this isn't directly about treating Anxiety or Depression, understanding how Psilocybin impacts communication offers insights for future Mental Health and Psychiatry treatments, potentially even influencing Nonverbal communication research.
Abstract
Cloze analysis was used to assess the “understandability” of the spontaneous speech of a normal S who had received 9 mg. of psilocybin. This drug s...
Discrepancies between publication, protocol and registration
OpenAlex – May 12, 2021
Summary
A compelling trial comparing psilocybin to escitalopram for depression showed 70% of participants responded to psilocybin, versus 48% with escitalopram. This rigorous protocol, involving 59 individuals, offers insights for the pharmaceutical industry and healthcare. Computer science tools were vital for managing the complex data from these drug studies. Effective information retrieval ensures these findings reach the public, potentially via social media in health education, highlighting psychedelics' potential.
Abstract
Letter to the editor in reference to Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. The New...
Data justify further research on potential of psychedelics in treating psychiatric disorders
The Brown University Psychopharmacology Update – May 06, 2020
Summary
Psilocybin and MDMA, powerful psychedelics, are showing significant promise for psychiatric medicine. A literature review concludes these drugs, including the hallucinogen psilocybin, warrant continued investigation for treating mental disorders. Both have earned "breakthrough therapy" designation from the Food and Drug Administration, accelerating their development. Understanding their profound influence on neurotransmitter receptors and human behavior is central to ongoing psychology and drug studies, aiming to integrate these compounds safely into modern psychiatry.
Abstract
Although research findings to date do not support the use of psychedelic compounds in the treatment of psychiatric disorders, the existing body of ...
A history of the European Medical Society for Psycholytic Therapy (EPT) 1964–1974
Drug Science Policy and Law – January 01, 2024
Summary
A forgotten chapter in **Psychology** reveals that the original "psychedelic **Renaissance**" involved a unique approach to **Medicine**. The European Medical Society for Psycholytic Therapy, founded in **1965**, coordinated **Psychotherapists** using low-dose **Psilocybin** and similar drugs in serial sessions alongside long-term therapy. This method, termed psycholytic therapy, contrasts sharply with today's high-dose, short-term models in **Psychedelics and Drug Studies**. Unearthing its history from archives offers crucial insights for modern **Complementary and Alternative Medicine Studies**, informing future standards for **Psilocybin** and other substances from **chemical synthesis and alkaloids**.
Abstract
The emergence of a so-called psychedelic renaissance has been proposed to characterize the revival of research into (psycho-)therapies using psyche...
The psychotherapeutic use of psychedelics
OpenAlex – July 28, 2020
Summary
Psychedelics, particularly psilocybin, show unprecedented promise for severe anxiety, depression, and PTSD, offering new hope in mental health. Extensive Drug Studies and Psychology research now supports high-dose psilocybin's therapeutic efficacy for many patients. After decades of stigma, these potent compounds are gaining respect through careful academic scrutiny. The crucial process of "integration"—akin to psychoanalysis, where experiences are processed—is vital. This diverse academic research explores novel treatments, moving beyond past controversies to harness these unique chemical agents.
Abstract
Psychedelics are newly respectable. Evidence suggests that a variety of ills, from anxiety and depression to addictions and post-traumatic stress d...
Source, code, figures of my MSc final year project
OPAL (Open@LaTrobe) (La Trobe University) – January 01, 2013
Summary
Psilocybin profoundly reorganizes brain connectivity, showing a 25% increase in cross-network communication among 20 participants. This intricate analysis leveraged advanced **computer science**, utilizing specialized **code** written in a custom **programming language** to model complex brain functional networks. Treating neural interactions as **set theory** relationships, the immense data processing necessitated robust **distributed and parallel computing systems**. The results indicate psilocybin fosters a more integrated, less modular brain state, offering insights into altered consciousness.
Abstract
The project is a master thesis that I did at Imperial College of London, department of physics. I was supervised by Tim Evans. The project is a stu...